Comparison of Taurine and Metformin on Paraoxonase Enzyme Activity and Lipid Profiles in Streptozotocin-Induced Diabetic Rats
Iranian Journal of Pharmaceutical Sciences,
Vol. 22 No. 1 (2026),
26 January 2026
,
Page 115-123
https://doi.org/10.22037/ijps.v22i1.46867
Abstract
Diabetes remains a pressing global health challenge, demanding innovative biochemical interventions for effective management. This study evaluates the effects of taurine and metformin on glucose regulation, lipid metabolism, and antioxidant enzyme activity in diabetic rats. Diabetes was induced in mice using a single intraperitoneal dose of streptozotocin (60 mg/kg), and animals with blood glucose levels exceeding 300 mg/dL were considered diabetic. The experimental subjects were systematically classified into four groups: healthy controls, diabetic controls, metformin-treated diabetics, and taurine-treated diabetics. Metformin and taurine were each administered via oral gavage at a dosage of 500 mg/kg/day for a period of one month, beginning seven days post-diabetes induction. Key indicators assessed included changes in body weight, fasting glucose levels, serum lipid components, and paraoxonase enzymatic activity. Metabolic evaluations included fasting blood glucose, body weight, lipid profile parameters, and paraoxonase enzyme activity. Metformin treatment did not significantly alter weight relative to the diabetic group, whereas taurine led to a notable improvement. Hyperglycemia was markedly reduced in both treatment groups compared to diabetic controls. Furthermore, analysis of lipid components revealed significant normalization: triglyceride, cholesterol, and LDL levels decreased, while HDL concentrations increased with both interventions. Antioxidant assessment showed restored paraoxonase activity in taurine- and metformin-treated animals.
These outcomes support the hypothesis that taurine and metformin contribute to the restoration of biochemical equilibrium in diabetic conditions. Both Taurine and metformin can modulate Diabetes-related metabolic disturbances, aiding in physiological stabilization. Both agents promoted glycemic correction, lipid improvement, and enzymatic recovery. Their efficacy suggests promise in supportive metabolic care for diabetes.
- glucose
- Blood glucose
- Metformin
- Diabetes
How to Cite
References
1. Zadabbas, H., M. Golbashirzadeh, and A. Moradzadegan, Exploring Cystatin C as an Early Indicator of End-Stage Diabetic Nephropathy in Patients With Type 2 Diabetes. Journal of Endocrinology and Metabolism, 2024. 14(5): p. 240-249.
2. Manucci, E., et al., Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subject. Diabetes Care, 2001. 4: p. 489-94.
3. Liang, J., et al., The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. Lipids in health and disease, 2020. 19: p. 1-7.
4. Mohammed, C.J., et al., A PON for all seasons: comparing paraoxonase enzyme substrates, activity and action including the role of PON3 in health and disease. Antioxidants, 2022. 11(3): p. 590.
5. Rojekar, M.V., K.S. Dandegonker, and S. Ghanghurde, Paraoxonase in Nervous System, in Acetylcholine-Recent Advances and New Perspectives. 2023, IntechOpen.
6. Ripps, H. and W. Shen, taurine: a “very essential” amino acid. Molecular vision, 2012. 18: p. 2673.
7. Grammatiki, M., R. Sagar, and R.A. Ajjan, Metformin: is it still the first line in type 2 diabetes management algorithm? Current Pharmaceutical Design, 2021. 27(8): p. 1061-1067.
8. Hayashi, T., Laboratory Animals published by the US National Institute were analyzed densitometrically by the National Institute of of Health (NIH Publication No. 85-23, revised 1996). Health HMAGE program, 2010.
9. Rezai, S., et al., Can combination therapy with insulin and metformin improve metabolic function of the liver, in type I diabetic patients? An animal model study on CYP2D1 activity. Journal of Diabetes & Metabolic Disorders, 2020. 19: p. 2049-2056.
10. Aborhyem, S., et al., Effect of Moringa oleifera on lipid profile in rats. Journal of High Institute of Public Health, 2016. 46(1): p. 8-14.
11. García, R.V., et al., Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome. Journal of Clinical Lipidology, 2022. 16(5): p. 635-642.
12. LaMoia, T.E. and G.I. Shulman, Cellular and molecular mechanisms of metformin action. Endocrine reviews, 2021. 42(1): p. 77-96.
13. Gutzwiller, J., et al., Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 1999. 44(1): p. 81-86.
14. Yu, M., B. Yu, and D. Chen, The effects of gut microbiota on appetite regulation and the underlying mechanisms. Gut Microbes, 2024. 16(1): p. 2414796.
15. Group, U.P.D.S., Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet, 1998. 352(9131): p. 854-865.
16. Pillon, N.J., et al., Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. Cell, 2021. 184(6): p. 1530-1544.
17. Yerevanian, A. and A.A. Soukas, Metformin: mechanisms in human obesity and weight loss. Current obesity reports, 2019. 8: p. 156-164.
18. Zhang, Q. and N. Hu, Effects of metformin on the gut microbiota in obesity and type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity, 2020: p. 5003-5014.
19. Kim, H.-J., et al., The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. Physiology & Behavior, 2016. 154: p. 184-190.
20. Lv, W.-s., et al., The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats. Brain research, 2012. 1444: p. 11-19.
21. Baker, C., et al., Should metformin remain the first-line therapy for treatment of type 2 diabetes? Therapeutic advances in endocrinology and metabolism, 2021. 12: p. 2042018820980225.
22. Inzucchi, S.E., et al., Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New England Journal of Medicine, 1998. 338(13): p. 867-873.
23. Agius, L., B.E. Ford, and S.S. Chachra, The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective. International journal of molecular sciences, 2020. 21(9): p. 3240.
24. Rafiee, Z., A.M. García-Serrano, and J.M. Duarte, Taurine supplementation as a neuroprotective strategy upon brain dysfunction in metabolic syndrome and diabetes. Nutrients, 2022. 14(6): p. 1292.
25. Schaffer, S. and H.W. Kim, Effects and mechanisms of taurine as a therapeutic agent. Biomolecules & therapeutics, 2018. 26(3): p. 225.
26. Tao, X., et al., The effects of taurine supplementation on diabetes mellitus in humans: A systematic review and meta-analysis. Food Chemistry: Molecular Sciences, 2022. 4: p. 100106.
27. Zhao, J. and Q. Xu, Influence of soybean meal on intestinal mucosa metabolome and effects of adenosine monophosphate-activated protein kinase signaling pathway in mirror carp (Cyprinus carpio songpu). Frontiers in Marine Science, 2022. 9: p. 844716.
28. Jin, M., et al., Examination of role of the AMP-activated protein kinase (Ampk) signaling pathway during low salinity adaptation in the mud crab, Scylla paramamosain, with reference to glucolipid metabolism. Aquaculture, 2024. 593: p. 741329.
29. Militante, J.D. and J.B. Lombardini, Dietary taurine supplementation: hypolipidemic and antiatherogenic effects. Nutrition Research, 2004. 24(10): p. 787-801.
30. Ebtehaj, S., et al., The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovascular diabetology, 2017. 16: p. 1-9.
31. Jaouad, L., C. Milochevitch, and A. Khalil, PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free radical research, 2003. 37(1): p. 77-83.
32. Nevin, D.N., et al., Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arteriosclerosis, thrombosis, and vascular biology, 1996. 16(10): p. 1243-1249.
33. Clark, G.J., K. Pandya, and C.A. Lau-Cam. The effect of metformin and taurine, alone and in combination, on the oxidative stress caused by diabetes in the rat brain. in Taurine 10. 2017. Springer.
34. Tahrani, A.A., T. Askwith, and M.J. Stevens, Emerging drugs for diabetic neuropathy. Expert opinion on emerging drugs, 2010. 15(4): p. 661-683.
35. Roxo, D.F., et al., Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats. Diabetology & metabolic syndrome, 2019. 11: p. 1-8.
- Abstract Viewed: 113 times
- IJPS_Volume22_Issue1_Pages115-123 Downloaded: 60 times